Gerstein Fisher buys $4,453,942 stake in Amedisys Inc (AMED)

Amedisys Inc (AMED) : Gerstein Fisher scooped up 19,798 additional shares in Amedisys Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 91,288 shares of Amedisys Inc which is valued at $4,453,942.Amedisys Inc makes up approximately 0.56% of Gerstein Fisher’s portfolio.

Other Hedge Funds, Including , Oxford Asset Management reduced its stake in AMED by selling 55,657 shares or 42.08% in the most recent quarter. The Hedge Fund company now holds 76,623 shares of AMED which is valued at $3,738,436. Amedisys Inc makes up approx 0.15% of Oxford Asset Management’s portfolio.Hanseatic Management Services Inc boosted its stake in AMED in the latest quarter, The investment management firm added 13,691 additional shares and now holds a total of 13,756 shares of Amedisys Inc which is valued at $690,689. Amedisys Inc makes up approx 0.25% of Hanseatic Management Services Inc’s portfolio. Gemmer Asset Management sold out all of its stake in AMED during the most recent quarter. The investment firm sold 140 shares of AMED which is valued $7,479.

Amedisys Inc opened for trading at $48.52 and hit $49.37 on the upside on Monday, eventually ending the session at $49.27, with a gain of 1.38% or 0.67 points. The heightened volatility saw the trading volume jump to 3,29,342 shares. Company has a market cap of $1,653 M.

On the company’s financial health, Amedisys Inc reported $0.40 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Mar 8, 2016. Analyst had a consensus of $0.35. The company had revenue of $338.37 million for the quarter, compared to analysts expectations of $322.02 million. The company’s revenue was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.

Many Wall Street Analysts have commented on Amedisys Inc. Shares were Downgraded by Mizuho on Aug 3, 2016 to ” Neutral” and Lowered the Price Target to $ 55 from a previous price target of $57 .

Amedisys Inc. (Amedisys) is a health care at home company. Amedisys delivers home health and hospice care to more than 360000 patients each year. The Company has care network across 34 states. As of December 31 2014 it owned and operated 316 Medicare-certified home health care centers and 80 Medicare-certified hospice care centers. The Company operates through two segments: home health and hospice. The Company’s home health segment delivers a range of services in the homes of individuals who may be recovering from surgery have a chronic disability or terminal illness or need assistance with the essential activities of daily living. The Company’s hospice segment provides palliative care and comfort to terminally ill patients and their families.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amedisys Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amedisys Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.